IDEXX Laboratories's (NASDAQ:IDXX) stock is 16.8% higher in the past 12 months and has outperformed the overall US TECH market which is 3.1% higher in the same timeframe. This equates to a 13.7% greater return over the period which puts the stock as an outperformer vs other US TECH companies.
From 10 analysts that cover IDEXX Laboratories's stock, the average rating is 3.9. This is a weighted average of 4 strong buys, 2 buys, 3 holds, 1 sells. This is 0.5 lower than a month ago which gives this factor a tea-score of 1/5.
IDEXX Laboratories insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 50.0% which is 49.0% higher than the last 12 months buy to sell ratio. This put's IDEXX Laboratories's Insiders in the top quintile vs their peers giving this factor a tea-score of 1/5.
For IDEXX Laboratories, currently 90.9% of stock (1 billion shares) is owned by Institutions, 7.5% (802 million shares) is owned by Individuals, and 1.6% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 3/5.
As of 31 July 2019, the short interest for IDEXX Laboratories has been 1.44% of the shares outstanding which is 12 billion shares. This is more than 1 month ago which had 1.30% of the shares outstanding which is 11 billion short interest in shares. This equals a tea-score of 4/5.
IDEXX Laboratories's revenue in the last 12 months ending 30 June 2019 is $2Bn. IDEXX Laboratories's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.
IDEXX Laboratories's free cash flow yield is 1.8% and has grown from 4 years ago. The free cash flow yield for IDEXX Laboratories 1 year ago was 2.2% and 3 years ago it was 2.2%.
IDEXX Laboratories hasn't paid any dividends for the past 4 years.
IDEXX Laboratories's PE ratio is 59.4x. This is calculated from their EPS of $2.02 and price per share of $275.41. IDEXX Laboratories's PE ratio values the company cheaper than 80% of it's competitors giving this factor a tea-score of 4/5.
IDEXX Laboratories's PEG ratio is 3.8x. This is calculated from their PE ratio of 59.4x and their last 12 months growth rate of 0.157%. This is more attractive than their competitors so the tea-score for this factor is 5/5.
The PB ratio for IDEXX Laboratories is 138.5x. This is cheaper than their competitors who have an average PB ratio of 8.1x. The tea-score is 5/5.
IDEXX Laboratories's free cash flow yield is 1.8% which is ranked 4.0/5 when compared to its competitors. This is calculated from a free cash flow of $372M (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $23Bn. The average free cash flow yield across IDEXX Laboratories's comps is 8.1%.
IDEXX Laboratories's return on investment is 623.3%. This is less profitable than its competitors.
IDEXX Laboratories's current ratio is calculated by (current assets) / (current liabilities) which equals 1.2x. This less attractive than their competitors and also worse than recommended for a healthy company.
IDEXX Laboratories's debt to shareholder equity is 604.1%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.
IDEXX Laboratories's has a poor overall ESG rating of 51/100. Their competitors have a score between 41 and 81 with the average at 59.
What is the 52 week high for IDEXX Laboratories stock quote?
IDEXX Laboratories (NASDAQ:IDXX) hit a new 52-week high on 18 July 2019 at a price of $289.85 with 360,700 shares traded that day. This is 5.2% higher than than its current price of $275.41 and 64.5% higher than the 52-week low of $176.18 on 24 December 2018. Average daily volume traded has been 378 thousand shares over the past 3 months.
What is the highest price IDEXX Laboratories stock has ever been?
The all-time highs for IDEXX Laboratories stock were reached on 18 July 2019, 32 days ago at a price of $289.85. This equates to a market capitalisation of $24Bn. The highest price reached is 5.2% higher than the current price of $275.41 with a current market cap of $23Bn.
What is the beta of IDEXX Laboratories stock?
IDEXX Laboratories stock moves 1.2x the US TECH market average which makes its beta higher than the overall market.
What is the volatility of IDEXX Laboratories (IDXX) stock?
IDEXX Laboratories's stock has an annual volatility of 28.5% which is more volatile than the average US TECH market volatility of 20.8% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.
What have IDEXX Laboratories's share buybacks been over the past year?
IDEXX Laboratories is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 16.8% higher which is an outperformance of 13.7% vs the overall market. IDEXX Laboratories still has $420Trn of cash remaining on their balance sheet.
Who owns the most IDEXX Laboratories stock?
Barry White is the largest individual shareholder in IDEXX Laboratories with 1 billion shares. He is an independent director of IDEXX Laboratories. The largest institutional holder is T-Rowe and they own 116.2% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.
When did IDEXX Laboratories beat earnings expectations in the last 4 years?
In the past 4 quarters IDEXX Laboratories has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.
When is IDEXX Laboratories's next earnings date and what are the expectations?
IDEXX Laboratories is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.
What is IDEXX Laboratories's upcoming earnings report expectations?
The earnings expectations for IDEXX Laboratories's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.
What is IDEXX Laboratories's earnings per share (EPS)?
IDEXX Laboratories's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82
What is IDEXX Laboratories's dividend growth rate?
What is IDEXX Laboratories's dividend yield?
What is IDEXX Laboratories's previous and next dividend date?